Next Article in Journal
Long-Term Deleterious Effects of Short-term Hyperoxia on Cancer Progression—Is Brain-Derived Neurotrophic Factor an Important Mediator? An Experimental Study
Next Article in Special Issue
The Multifactorial Role of PARP-1 in Tumor Microenvironment
Previous Article in Journal
Vitamin C Restricts the Emergence of Acquired Resistance to EGFR-Targeted Therapies in Colorectal Cancer
Previous Article in Special Issue
The Controversial Roles of ADP-Ribosyl Hydrolases MACROD1, MACROD2 and TARG1 in Carcinogenesis
Open AccessReview

ATM-Deficient Cancers Provide New Opportunities for Precision Oncology

Department of Biochemistry and Molecular Biology, Robson DNA Science Centre, Charbonneau Cancer Institute, Cumming School of Medicine, University of Calgary, 3330 Hospital Drive NW, Calgary, AB T2N 1N4, Canada
Tom Baker Cancer Centre, 1331 29 St NW, Calgary, AB T2N 4N2, Canada
Cross Cancer Institute, 11560 University Avenue NW, Edmonton, AB T6G 1Z2, Canada
Author to whom correspondence should be addressed.
Cancers 2020, 12(3), 687;
Received: 14 February 2020 / Revised: 9 March 2020 / Accepted: 12 March 2020 / Published: 14 March 2020
(This article belongs to the Special Issue PARPs, PAR and NAD Metabolism and Their Inhibitors in Cancer)
Poly-ADP ribose polymerase (PARP) inhibitors are currently used in the treatment of several cancers carrying mutations in the breast and ovarian cancer susceptibility genes BRCA1 and BRCA2, with many more potential applications under study and in clinical trials. Here, we discuss the potential for extending PARP inhibitor therapies to tumours with deficiencies in the DNA damage-activated protein kinase, Ataxia-Telangiectasia Mutated (ATM). We highlight our recent findings that PARP inhibition alone is cytostatic but not cytotoxic in ATM-deficient cancer cells and that the combination of a PARP inhibitor with an ATR (ATM, Rad3-related) inhibitor is required to induce cell death. View Full-Text
Keywords: ATM; olaparib; ATR; PARP; PARP inhibitor; prostate cancer; pancreatic cancer; lung cancer ATM; olaparib; ATR; PARP; PARP inhibitor; prostate cancer; pancreatic cancer; lung cancer
Show Figures

Figure 1

MDPI and ACS Style

Jette, N.R.; Kumar, M.; Radhamani, S.; Arthur, G.; Goutam, S.; Yip, S.; Kolinsky, M.; Williams, G.J.; Bose, P.; Lees-Miller, S.P. ATM-Deficient Cancers Provide New Opportunities for Precision Oncology. Cancers 2020, 12, 687.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

Search more from Scilit
Back to TopTop